Cipla, Roche In Court-Ordered Mediation Over India Tarceva Patent
This article was originally published in PharmAsia News
Cipla and Roche have begun negotiating between themselves their dispute over Roche's India patent for its Tarceva (erlotinib) lung-cancer drug after the Delhi High Court pressured them to mediate.
You may also be interested in...
Medical supplies manufacturers can collaborate to address the novel coronavirus pandemic without violating antitrust law, the US Department of Justice has said.
The submission of more trial data from Roche has prompted the US FDA to extend by three months its decision on whether to approve risdiplam for spinal muscular atrophy.
A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.